首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   28728篇
  免费   1651篇
  国内免费   123篇
医药卫生   30502篇
  2023年   283篇
  2022年   337篇
  2021年   1110篇
  2020年   774篇
  2019年   948篇
  2018年   1143篇
  2017年   794篇
  2016年   864篇
  2015年   1032篇
  2014年   1356篇
  2013年   1592篇
  2012年   2367篇
  2011年   2589篇
  2010年   1288篇
  2009年   946篇
  2008年   1754篇
  2007年   1736篇
  2006年   1395篇
  2005年   1268篇
  2004年   1059篇
  2003年   977篇
  2002年   859篇
  2001年   498篇
  2000年   470篇
  1999年   414篇
  1998年   145篇
  1997年   86篇
  1996年   77篇
  1995年   78篇
  1994年   83篇
  1993年   58篇
  1992年   183篇
  1991年   169篇
  1990年   158篇
  1989年   143篇
  1988年   136篇
  1987年   85篇
  1986年   90篇
  1985年   82篇
  1984年   59篇
  1983年   55篇
  1979年   74篇
  1978年   43篇
  1974年   53篇
  1973年   57篇
  1970年   73篇
  1969年   77篇
  1968年   58篇
  1967年   67篇
  1966年   51篇
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
991.
992.
We evaluated the influence of allelic frequency of the human leukocyte antigen (HLA) -DRB1 on the acquisition of antibody response against malaria sporozoite and merozoite peptides in patients with Plasmodium vivax malaria acquired in endemic areas of Brazil. IgG antibodies were detected by enzyme-linked immunosorbent assay against four peptides of circumsporozoite protein (CSP) (amino, carboxyl, and VK210 and VK247 repeats) and peptides of merozoite surface protein 1 (MSP-1), apical membrane antigen 1 (AMA-1), and Duffy-binding protein (DBP). We found an association between HLA-DR3 and HLA-DR5 alleles and lack of antibody response to CSP amino terminal, as well as an association between HLA-DR3 and the highest antibody response to MSP1 (Pv200L). In conclusion, we suggest a potential regulatory role of the HLA-DRB1 alleles in the production of antibodies to a conserved region of P. vivax CSP and MSP1 in Brazilian population exposed to malaria.  相似文献   
993.
994.
Dengue fever has been a major problem in hospital settings in Brazil for the past 15 years. The main concern has been the severe forms, i.e., dengue hemorrhagic fever and dengue shock syndrome. Hemorrhagic events of different degrees have also been a major concern. We report five cases of large vein thrombotic events associated with the acute phase of dengue fever, including a previously non-reported case of mesenteric vein thrombosis. Complications such as these could have been overlooked in the diagnosis of dengue fever, given that the major concern is the hemorrhagic event.Dengue fever frequently affects Brazil, where thousands of cases have been diagnosed annually and all four dengue virus serotypes (DENV-1 through DENV-4) have been reported, sometimes concurrently in the same region.1,2 Hemorrhagic events of different degrees have often been described in dengue, but thrombotic events have not been extensively reported, despite the wide range of increased procoagulant activity during illness.1,38 During a recent outbreak, several cases of thrombotic events affected large veins in dengue fever patients. We report cases of unusual and overlooked complication of dengue fever.From January 2011 through March 2011 during a local outbreak of dengue fever caused by DENV-1 and DENV-2 according to local health officials, five patients were given diagnoses by imaging techniques (pulmonary computed tomography angiography, cholangio-magnetic resonance imaging, and Doppler ultrasound of lower extremities) as having large vessel thrombosis. These patients were part of 92 serologically confirmed (by immunochromatographic strip test or IgM antigen-capture enzyme-linked immunosorbent assay) patients with dengue (60% women and 40% men, median age = 39 years, age range = 10–99 years) admitted to Monte Sinai Hospital (200 beds) in Juiz de Fora, (population = 500,000), Minas Gerais, Brazil. This study was approved by the Ethical Committee of Monte Sinai Hospital.Twenty-three patients (25%) were classified as having dengue shock syndrome or dengue hemorrhagic fever and 4 deaths were recorded (case-fatality rate = 4.3%). These thrombotic patients represented 5.4% of all dengue inpatients. All thrombotic events were identified within the first five days of illness, and all patients had symptoms compatible with the reported thrombotic event at hospital admission. No thrombotic events were identified among the remaining patients during hospitalization, and none of the patients them received drugs for thrombosis prophylaxis, which is contraindicated in dengue.The demographic and clinical characteristics of the five patients are summarized in Figure 1), which was associated with jaundice and severe sepsis by Escherichia coli demonstrated by blood culture. Known risk factors for thrombotic events such as smoking, use of oral contraceptives, and being overweight were absent in all patients and none had had any similar diagnosis or symptoms.Open in a separate windowFigure 1.T1-weighted cholangio-magnetic resonance image with contrast of dengue patient 5 showing the superior mesenteric vein (SMV) with a large thrombus (arrow) occupying the vein lumen. SMA = superior mesenteric artery; IVC = inferior vena cava; Ao = aorta.

Table 1

Demographic, clinical, and laboratory characteristics of five dengue fever patients with thrombotic events, Brazil*
Patient/age (years)/sexPlatelets (× 109/L)Hematocrit, %Antibodies against phospholipid§ImagingManifestationsThrombotic eventIllness day of thrombosis diagnosis
1/89/F11333IgG 4.5, IgM 17.6Doppler USLeg pain and edemaDVT2
2/41/F11232.9IgG 7.9, IgM 1.9Doppler USLeg pain and edemaDVT3
3/89/F5245IgG 32.8, IgM 14.2CTADyspneaPTE1
4/51/F4541IgG 0.6, IgM 12.0CTADyspneaPTE2
5/61/M3742IgG 6.1, IgM 11.3C-MRISIRSMVT5
Open in a separate window*US = ultrasound; DVT = deep vein thrombosis; CTA = computed tomography angiography; PTE = pulmonary thromboembolism; C-MRI = cholangio-magnetic resonance imaging; SIRS = systemic inflammatory response syndrome; MVT = mesenteric vein thrombosis.Reference value = 140–400 × 109 /L (sample obtained on hospital day 1).Reference values: males = 41–53%; females = 36–46% (sample obtained on hospital day 1).§Reference value < 10 IgMPL/IgGPL (IgM phospholipid units, 1 IgMPL unit = 1 μg of IgM); IgGPL (IgG phospholipid units, 1 GPL unit = 1 μg of IgG).Increased levels of IgM against phospholipids were detected in four patients, but levels of IgG against phospholipids above the reference level were detected in only one patient (by enzyme immunoassay), and this was the only positive result in thrombophilia screening. Although most of the patients were dehydrated, severe hemoconcentration was not observed. Leukocyte counts were within the reference range and levels of D-dimer were increased in all patients. The international normalized ratio (prothrombin time) was normal or slightly prolonged in all patients and none had hemorrhagic events. None of the thrombotic patients were classified as having dengue shock syndrome or dengue hemorrhagic fever. All patients were treated with low molecular weight heparin and recovered. Although not completely understood, low platelet counts and function, increased vascular permeability, increased thrombomodulin, increased tissue plasminogen activator, and antibody cross-reactivity with endothelial cells and with specific coagulation proteins are among the suggested mechanisms responsible for hemorrhagic phenomena in dengue fever.38Myriad factors, including cytokines, fibrinolysis, and the complement system, might increase thrombotic risk in dengue fever patients.35 Increased PAI-1 plasma levels seem to be common in DENV infection and have been associated with greater risk for thrombosis.7 Disseminated intravascular coagulation and consequent microthombi formation have also been reported in dengue fever but have not been associated with large vessel thrombosis.5 Low concentrations of plasma anticoagulant proteins C and S and antithrombin III have also been detected in severe dengue but have not been associated with clinical thrombosis.4Increased levels of IgM against phospholipids were detected in all but one patient in this series, but these levels are of low clinical significance for thrombosis. Thus, except for increased levels of IgG against phospholipids in one patient, no other procoagulant risk factor was identified in this case series.9 Antibodies against phospholipids and increased lupus anticoagulant have been anecdotally associated with thrombotic events in peripheral arteries and cerebral vasculature in dengue fever patients.10,11 Venous cerebral vasculature thrombosis and ischemic stroke not associated with antibodies against phospholipids or other risk factors have been rarely reported in dengue fever patients.12Severe dehydration, a well known condition associated with thrombotic events, was not detected in any patient. All but one of the patients was > 50 years of age. Thus, the role of older age in thrombotic events in dengue fever should be considered. It is noteworthy that none of the thrombosis cases occurred in patients with dengue shock syndrome or dengue hemorrhagic fever, but the small number of patients with these conditions is not a reasonable explanation.The involved mechanism seems to be related to events that occurred during the early phase of the disease because the thrombotic events were clinically detected at admission and no episode of thrombosis was detected among the remaining dengue fever patients throughout hospitalization or during outpatient follow-up. Loss of endothelium non-thrombogenic protective factors has been identified in severe dengue early in the course of the disease.1To our knowledge, deep vein thrombosis, pulmonary thromboembolism, and mesenteric vein thrombosis have not been reported in direct association with dengue fever.1,11,12 Mesenteric vein thrombosis was an unusual complication of DENV infection, and was erroneously diagnosed in an imaging study of suspected cholangitis in a patient with clinical sepsis without a primary source. Awareness for these kinds of complications should be recommended to all practitioners who treat patients with dengue fever, particularly in hospital settings.  相似文献   
995.
996.
997.
998.
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号